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ORIGINAL ARTICLE
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Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; fDepartment of Nuclear Medicine and Molecular
Imaging, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; gDepartment of Pulmonology, GROW-
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ABSTRACT
Background: Standardization protocols and guidelines for positron emission tomography (PET) in mul-
ticenter trials are available, despite a large variability in image acquisition and reconstruction parame-
ters exist. In this study, we investigated the compliance of PET scans to the guidelines of the European
Association of Nuclear Medicine (EANM). From these results, we provide recommendations for future
multicenter studies using PET.
Material and methods: Patients included in a multicenter randomized phase II study had repeated
PET scans for early response assessment. Relevant acquisition and reconstruction parameters were
extracted from the digital imaging and communications in medicine (DICOM) header of the images.
The PET image parameters were compared to the guidelines of the EANM for tumor imaging version
1.0 recommended parameters.
Results: From the 223 included patients, 167 baseline scans and 118 response scans were available
from 15 hospitals. Scans of 19% of the patients had an uptake time that fulfilled the Uniform Protocols
for Imaging in Clinical Trials response assessment criteria. The average quality score over all hospitals
was 69%. Scans with a non-compliant uptake time had a larger standard deviation of the mean stand-
ardized uptake value (SUVmean) of the liver than scans with compliant uptake times.
Conclusions: Although a standardization protocol was agreed on, there was a large variability in imaging
parameters. For future, multicenter studies including PET imaging a prospective central quality review dur-
ing patient inclusion is needed to improve compliance with image standardization protocols as defined
by EANM.
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Background
Many studies have shown that 18F-fluorodeoxy glucose posi-
tron emission tomography (18F-FDG-PET) can be used for
early response assessment [1–5]. Treatment response is meas-
ured by the relative change in standardized uptake value
(SUV) during treatment. Many factors affect SUV, such as
patient preparation procedures, acquisition parameters and
reconstruction parameters. Therefore, if response assessment
using 18F-FDG-PET data is performed in multicenter studies,
it is of utmost importance that acquisition and reconstruction
are standardized. Also in preclinical research the develop-
ment of PET as a predictive tool is desirable. However, reach-
ing a high degree of reproducibility and sensitivity in small
animal studies using FDG-PET is also challenging. Therefore,
it is important to minimize methodological issues in
preclinical as well as clinical studies as much as possible by
standardize acquisition and reconstruction [6].
In 2010, the European Association of Nuclear Medicine
(EANM) published the tumor PET imaging guidelines version
1.0, which give a minimum standard for acquisition and
reconstruction of FDG-PET scans [7]. This protocol standard-
izes patient preparation, FDG dosage, reconstruction settings,
data analysis and include a multicenter quality control phan-
tom measurement procedure [7–10].
In 2011, the multicenter randomized phase II NVALT12
(NCT01171170) study in stage IV non-small cell lung cancer
started. Part of this study was an imaging sub-study, where
repeated 18F-FDG-PET imaging for early response assessment
was performed [11]. In the NVALT12 protocol, it was assumed
that the EANM 1.0 imaging guidelines had been imple-
mented in the hospitals and that 18F-FDG-PET scans were
CONTACT Anne-Marie C. Dingemans a.dingemans@mumc.nl Department of Pulmonology, GROW-School for Oncology and Developmental Biology,
Maastricht University Medical Centre, P. Debyelaan 25, Maastricht, 6229 HX, Netherlands
Supplemental data for this article can be accessed here.
 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/
4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon
in any way.
ACTA ONCOLOGICA, 2017
VOL. 56, NO. 11, 1459–1464
https://doi.org/10.1080/0284186X.2017.1346824
performed according to these guidelines. EANM 1.0 recon-
struction of the 18F-FDG-PET images was recommended,
although reconstruction might be performed according to insti-
tutional standards and therefore variability in image parameters
could be expected.
In this study, we investigated the quality of the 18F-FDG-
PET scans in the NVALT12 study and the impact of deviations
on the mean SUV of the liver. By identifying the sources of
variability, we derived recommendations for future reduction
of these uncertainties for early response assessment.
Material and methods
Between January 2011 and January 2013, a total of 223
patients were included in the NVALT12 study [12]. The base-
line 18F-FDG-PET scan was standard of care, and only for
patients who had an 18F-FDG-PET at baseline as part of the
standard work-up for lung cancer a second 18F-FDG-PET
scan was performed. Scans were anonymized locally and per
CD sent to the central hospital were the analysis was done.
One hundred and sixty-seven baseline 18F-FDG-PET scans
and 118 response 18F-FDG-PET scans were retrieved. Scans
that could not be converted to SUV (i.e., SUV conversion
information missing) were also excluded (baseline n¼ 9;
response n¼ 9), which meant that only for 158 baseline
scans and 109 response scans the SUVmean of the liver
could be analyzed. The 18F-FDG-PET scans were obtained in
a multicentric setting from 15 different hospitals using PET
scanners from three different vendors: vendor A (Philips
Healthcare, Best, the Netherlands), vendor B (GE Healthcare,
Chicago, IL, USA) and vendor C (Siemens Healthineers,
Erlangen, Germany).
For the quality analysis, we performed a Digital Imaging
and Communications in Medicine (DICOM) header extraction
to extract the radiopharmaceutical start time, series time,
attenuation correction method, randoms correction method,
scatter correction method, reconstruction method, convolu-
tion kernel width and matrix size.
To check the quality of the 18F-FDG-PET scans, the image
acquisition and reconstruction parameters extracted from the
DICOM header were compared to the acquisition and recon-
struction parameters as recommended by the EANM 1.0. In
the paragraphs below the EANM parameters that were used
for the quality check are described.
Uptake time
The EANM 1.0 guidelines recommend that emission scanning
should start 55–65min after FDG administration. To test if
the scans of a patient could be used for response assessment
the Uniform Protocol for Imaging in Clinical Trials (UPICT) cri-
teria were used. The UPICT protocol specifies that when a
scan is repeated on the same patient, it is important that the
uptake time is consistent with an acceptable variance of
±15min, provided that both scans do not start before 55min
after FDG administration [10]. The uptake time in our study
was the difference in time between the radiopharmaceutical
start time and the start of the PET acquisition (i.e., DICOM
series time).
Corrections
In order to obtain the quantitative information from a 18F-
FDG-PET scan, an attenuation correction and corrections for
random and scatter coincidences are required [13]. Different
methods to correct for randoms and scatter exist, depending
on the specific implementation at the scanner and the
vendor. For this analysis, it was only checked if the correction
was applied.
Image reconstruction
Based on a phantom study in 2008, most PET/CT scanners pro-
vide images with a spatial resolution close to 7mm full width
at half maximum (FWHM) when using the default by the manu-
facturer-recommended image reconstruction settings [9].
Other settings, such as smoothing filters and image matrix size
can be changed with preservation of a final image resolution
of approximately 7mm FWHM and harmonized interpretation
and analysis of multicenter data is possible.
The scans in this study were performed on eight different
PET scanners from three different vendors: 41% (69/167) of the
scans were performed on a scanner of vendor A, 2% (4/167) on
a scanner of vendor B and 56% (94/167) on a scanner of
vendor C. For scans performed on a scanner of vendor B or C,
the indicative reconstruction settings are a matrix size of
128 128 or 256 256, a post-reconstruction smoothing using
a 5–6mm FWHM Gaussian filter and a 2D/3D ordered subset
expectation maximization (OSEM) reconstruction with the
number of iterations times the number of subsets above 30.
For scans performed on a scanner of vendor A, the indicative
reconstruction settings are a matrix size of 144 144 and a
line-of-response row-action-maximum likelihood-algorithm
(LOR-RAMLA)/3D RAMLA/3D ordered-subset iterative time-of-
flight (BLOB-OS-TF) reconstruction method. For reconstructions
with point spread function (PSF) corrections, the post-recon-
struction smoothing need to be increased to 7–8mm.
Quality score
To check possible differences in PET quality between the dif-
ferent hospitals we scored every scan individually and calcu-
lated the average score of the scans per hospital. For every
correct parameter, the scan received a point and the number
of points per scan were divided by the number of known
parameters for that scan, so missing data were excluded
from the quality score.
Influence on SUV
To investigate the influence of image parameters on SUV, a
spherical volume of interest with a diameter of 3 cm was
delineated in the right lobe of the liver [14]. A mean SUV of
the liver between 1.3 and 2.5 was defined as a correct quality
scan [8].
Results
There were only a few scans with differences in reconstruc-
tion parameters between the baseline scan and the response
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scan; some patients had the baseline scan on a scanner of
vendor C and the response scan on a scanner of vendor A
(n¼ 2) and some other patients had the baseline scan with-
out PSF and the response scan with PSF (n¼ 2) (see also
Figure 1).
About one-third of the scans (35%; 97/280) of all scans
had an uptake time between 55 and 65min. Twelve percent
(14/118) of the scans had an uptake time between 55 and
65min for the baseline scan and for the response scan
(Figure 2). Due to the range in uptake time we calculated
the median instead of the mean. The median uptake time
was 64min for the baseline scan as well as for the response
scan (see also Table S1). In 11 patients both scans had an
uptake time less than 55min. In only 19% (53/285) of the
patients, both scans had an uptake time of more than 55min
and a difference of less than 15min between the two scans
and could therefore be used for response assessment accord-
ing to UPICT.
The corrections for attenuation, random and scatter coin-
cidences could be retrieved for 86% (144/167) of the baseline
scans and for 78% (92/118) of the response scans (S1). For
the other scans the information was missing. Scans that had
missing information were from the same hospital (see also
Figure 1).
About 50% of the baseline scans and 50% of the response
scans performed on a scanner of vendor A were
reconstructed according to the EANM 1.0 guidelines. For 24%
of the baseline scans and 25% of the response scans per-
formed on a scanner of vendor A the reconstruction method
was missing. For the scans performed on a scanner of vendor
B or C a large variability in reconstruction method existed.
Thirty-three percent of the baseline scans and 37% of the
response scans performed on a scanner of vendor B or C
were reconstructed according to the EANM 1.0 guidelines.
No reconstruction parameters were missing for the scans per-
formed on a scanner of vendor B or C.
The average quality score over all hospitals was 0.69 (0.46;
0.88), which means that on average more than two-third of
the image parameters were EANM 1.0 guideline compliant.
Hospitals with a scanner of vendor A scored on average
slightly higher than hospitals with a scanner of vendor B or C
(vendor A: 0.80 (range: 0.56–0.88); vendor B/C: 0.64
(0.46–0.88)).
Although there was a large variability in image parame-
ters, most scans had a SUVmean of the liver which was
EANM 1.0 guideline compliant (64%; 171/267), only 5%
(8/158) of the baseline scans and 2% (2/109) of the response
scans had a SUVmean below 1.3. Twenty percent (53/267) of
the scans had a SUVmean of the liver as well as an uptake
time that was EANM 1.0 guideline compliant (Figure S2).
There was no difference in mean SUVmean of the liver for
baseline or response scans with an EANM 1.0 or UPICT com-
pliant uptake time. When looking at the scans with a non-
guideline compliant uptake time, the mean SUVmean of the
liver is comparable 2.33 for the baseline scan and 2.23 for
the response scan although the standard deviation is slightly
increased 0.62 for the baseline scan and 0.49 for the
response scan.
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Figure 2. Time interval between injection and start time of scan per patient
ranked in ascending order for the baseline scan. The horizontal lines show the
NEDPAS specified maximum (65) and minimal (55) uptake times. One outlier



































Figure 1. (A) Heatmap of the image parameters of the baseline scan ranked in
descending order according to the quality score of the hospital. (B) Heatmap of
the difference in image parameters between the baseline scan and the response
scan ranked in descending order according to the quality score of the hospital.
Green: EANM guideline compliant, white: missing information, orange:
improved for response scan, red: EANM guideline non-compliant/worsened for
response scan, striped: response scan on different scanner than baseline scan.
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In Figure 3, the hospitals were ranked in descending order
according to their quality score and there seems no trend
between the quality score of the hospital and the variability
in SUVmean of the liver. No difference in SUVmean of the
liver was found for the different vendors.
Discussion
Despite the availability of imaging guidelines for 18F-FDG-
PET [7–10,15], our analysis shows that a large variability in
image acquisition and reconstruction parameters existed
in the 18F-FDG-PET scans of the multicenter NVALT12 trial. In
this study, we investigated the number of 18F-FDG-PET scans
of the NVALT12 study that were EANM 1.0 guideline compli-
ant and the impact of deviations on SUV. Next to that, we
speculate about possible reasons for deviations from this
guideline.
The EANM 1.0 guideline recommend that PET imaging
takes place 60±5min after administration of FDG [9]. This
uptake time window is essentially empiric and determined
taken financial considerations into account, and probably not
optimal [15]. It is well known that lesion SUV for FDG contin-
ues to rise for at least 45min after FDG injection, reaching a
plateau between 60 and 90min [16,17]. In our study, only 34%
of all scans had an uptake time as recommended by the
EANM 1.0. With that we show that in clinical practice it is hard
to have an uptake time within the recommended window of
10min. In the EANM guidelines version 2.0, this is changed to
an acceptable uptake time window of 55–75min, 59% of the
scans in this study had an uptake time within this window.
Another possible reason for deviations is that the radiophar-
maceutical start time extracted from the DICOM header was
not the time of FDG administration as we assumed. Because it
is currently not possible to separately store information on
injection time and calibration time in the DICOM header,
some ambiguity which time is in the DICOM header under the
name radiopharmaceutical start time exists [18].
Reconstruction algorithms and voxel size are different for
the various available PET systems and vendor dependent.
Therefore, it is a challenge to ensure that images of PET
scanners from different vendors are quantitatively compar-
able [15]. Multiple studies have shown that liver metabolism
can be used as reference organ due to its stable uptake over
time and therefore suitable for assessment of scan parame-
ters [18]. We therefore used the SUVmean of liver as quality
control measure. However, our results did not show a rela-
tion between the quality score and SUVmean of the liver.
Kuhnert et al. [19] showed that for parameters other than
reconstruction method and settings (injected activity and
uptake time for example), the SUVmean of the liver could be
used for quality assessment in compliance with the EANM
guideline, meaning that the large variability in SUVmean of
the liver is most probably caused by the differences in
uptake time and net injected activity. We showed that like
Hristova et al. [18] the variability in SUVmean of the liver is
slightly smaller for the scans with a guideline compliant
uptake time than for the scans with non-compliant uptake
times (SUVmean 2.29 ± 0.46 vs. 2.33 ± 0.62).
The hospital analysis showed that the average score over
all hospitals is 0.69 and that scans from the same hospital
mostly have the same non-compliant image parameters.
Scans with missing parameters are typically from the same
hospitals which is most probably caused by the anonymiza-
tion procedure.
Our study shows that in a multicenter trial still a large
variability in image parameters exist. Especially when using
Figure 3. Boxplot of SUVmean of the liver of the baseline scan ranked in descending order according to the quality score and per vendor, the scans of hospital A
were, due to a missing SUV conversion tag, not converted to SUV and are therefore empty in the graph.
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the PET information for treatment decisions, like in dose
painting the high uptake region [20], it is important that
acquisition and reconstruction are standardized, otherwise
different sub-volumes will be boosted. When more complex
analysis methods (e.g., Radiomics) are used to predict therapy
response using PET in the future, it is important that image
acquisition and reconstruction are standardized [21]. A study
of Carvalho et al. [22] investigated next to common PET
descriptors like SUVmax and SUVpeak if more complex
descriptors like intensity volume histograms of the PET signal
are prognostic in NSCLC. They only found a trend that
patients with tumors with a more homogeneous distribution
of SUV had a better prognosis [22]. Although they only had
data from one hospital, the image protocol changed during
inclusion criteria and therefore variability in SUV could be
present what could have caused the non-significance of
SUVmax for prognosis.
A few recommendations for future multicenter studies
with repeated PET imaging are drawn. For drafting the study
protocol, it is recommended to collaborate with radiologists
and nuclear medicine experts to assure access to the current
imaging guidelines to keep the variability in image acquisi-
tion and reconstruction parameters as low as possible. Next,
it is recommended to use an anonymization process that
keeps all DICOM fields necessary for SUV quantification and
investigation of the acquisition and reconstruction parame-
ters. For calculating the uptake time, take the acquisition
time near the midplane slice of the tumor. A final recommen-
dation in a multicenter trial setting using 18F-FDG-PET
involves a prospective rapid quality review, which is a good
procedure to improve compliance with imaging guidelines
and tackle difficulties in image sharing and processing as
early as possible [18]. More details of these recommendations
can be found in Table S3.
In conclusion, although guidelines for tumor imaging
exist, there is still a large variability in acquisition and recon-
struction parameters of 18F-FDG-PET imaging in multicenter
studies. In the future, these variations should be minimized
by performing a rapid quality review that tackle difficulties in
image sharing and processing as early as possible.
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